Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1

被引:21
作者
Selley, E. [1 ,2 ]
Kun, S. [1 ,2 ]
Szijarto, I. A. [3 ,4 ]
Kertesz, M. [1 ,2 ]
Wittmann, I. [1 ,2 ]
Molnar, G. A. [1 ,2 ]
机构
[1] Univ Pecs, Dept Med 2, Pecs, Hungary
[2] Univ Pecs, Nephrol Ctr, Pecs, Hungary
[3] Charite Campus Virchow Klinikum, Med Clin Nephrol & Internal Intens Care, Berlin, Germany
[4] Max Delbruck Ctr Mol Med, ECRC, Berlin, Germany
关键词
aortic rings; glucagon; GLP-1; vasodilatation; INSULIN-INDUCED RELAXATION; SMOOTH-MUSCLE-CELLS; FATTY LIVER-DISEASE; ANTIDIABETIC AGENTS; MECHANISM; ARTERIES; SECRETION; CHANNELS; INCREASE; INJURY;
D O I
10.1055/s-0042-101794
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucagon is known for its insulin-antagonist effect in the blood glucose homeostasis, while it also reduces vascular resistance. The mechanism of the vasoactive effect of glucagon has not been studied before; thereby we aimed to investigate the mediators involved in the vasodilatation induced by glucagon. The vasoactive effect of glucagon, insulin, and glucagon-like peptide-1 was studied on isolated rat thoracic aortic rings using a wire myograph. To investigate the mechanism of the vasodilatation caused by glucagon, we determined the role of the receptor for glucagon and the receptor for GLP-1, and studied also the effect of various inhibitors of gasotransmitters, inhibitors of reactive oxygen species formation, NADPH oxidase, prostaglandin synthesis, protein kinases, potassium channels, and an inhibitor of the Na+/Ca2+-exchanger. Glucagon causes dose-dependent relaxation in the rat thoracic aorta, which is as potent as that of insulin but greater than that of GLP-1 (7-36) amide. Vasodilatation by GLP-1 is partially mediated by the glucagon receptor. The vasodilatation due to glucagon evokes via the glucagon-receptor, but also via the receptor for GLP-1, and it is endothelium-independent. Contribution of gasotransmitters, prostaglandins, the NADPH oxidase enzyme, free radicals, potassium channels, and the Na+/Ca2+ -exchanger is also significant. Glucagon causes dose-dependent relaxation of rat thoracic aorta in vitro, via the receptor for glucagon and the receptor for GLP-1, while the vasodilatation evoked by GLP-1 also evolves partially via the receptor for glucagon, thereby, a possible crosstalk between the 2 hormones and receptors could occur.
引用
收藏
页码:476 / 483
页数:8
相关论文
共 50 条
  • [31] The role of glucagon-like peptide 1 (GLP-1) in addictive disorders
    Kruse Klausen, Mette
    Thomsen, Morgane
    Wortwein, Gitta
    Fink-Jensen, Anders
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 625 - 641
  • [32] Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
    Modrzynska, Justyna
    Klein, Christine F.
    Iversen, Kasper
    Bundgaard, Henning
    Hartmann, Bolette
    Mose, Maike
    Rittig, Nikolaj
    Moller, Niels
    Holst, Jens J.
    Albrechtsen, Nicolai J. Wewer
    ENDOCRINE CONNECTIONS, 2021, 10 (02) : 205 - 213
  • [33] Studies on glucagon like peptide-1 (GLP-1) analogues: a review
    Jiang J.-Q.
    Fu L.
    Tan M.-L.
    Chen S.-F.
    Gao Xiao Hua Xue Gong Cheng Xue Bao/Journal of Chemical Engineering of Chinese Universities, 2020, 34 (06): : 1327 - 1338
  • [34] Preanalytical impact on the accuracy of measurements of glucagon, GLP-1 and GIP in clinical trials
    Rasmussen, Christine
    Richter, Michael M.
    Jensen, Nicole J.
    Heinz, Niklas
    Hartmann, Bolette
    Holst, Jens J.
    Kjeldsen, Sasha A. S.
    Albrechtsen, Nicolai J. Wewer
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2023, 83 (08) : 591 - 598
  • [35] Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition
    Patel, Vishal
    Joharapurkar, Amit
    Kshirsagar, Samadhan
    Sutariya, Brijesh
    Patel, Maulik
    Pandey, Dheerendra
    Patel, Hiren
    Ranvir, Ramchandra
    Kadam, Shekhar
    Patel, Dipam
    Bahekar, Rajesh
    Jain, Mukul
    CHEMICO-BIOLOGICAL INTERACTIONS, 2018, 282 : 13 - 21
  • [36] Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies Treatment
    Foltynie, Tom
    Athauda, Dilan
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2018, 5 (03): : 255 - 258
  • [37] Altered Glucagon and GLP-1 Responses to Oral Glucose in Children and Adolescents With Obesity and Insulin Resistance
    Stinson, Sara Elizabeth
    Alzola, Ierai Fernandez de Retana
    Hovendal, Emilie Damgaard Brunner
    Lund, Morten Asp Vonsild
    Fonvig, Cilius Esmann
    Holm, Louise Aas
    Jonsson, Anna Elisabet
    Frithioff-Bojsoe, Christine
    Christiansen, Michael
    Pedersen, Oluf
    Angquist, Lars
    Sorensen, Thorkild I. A.
    Holst, Jens Juul
    Hartmann, Bolette
    Holm, Jens-Christian
    Hansen, Torben
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (06) : 1590 - 1600
  • [38] A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets
    P. Marchetti
    R. Lupi
    M. Bugliani
    C. L. Kirkpatrick
    G. Sebastiani
    F. A. Grieco
    S. Del Guerra
    V. D’Aleo
    S. Piro
    L. Marselli
    U. Boggi
    F. Filipponi
    L. Tinti
    L. Salvini
    C. B. Wollheim
    F. Purrello
    F. Dotta
    Diabetologia, 2012, 55 : 3262 - 3272
  • [39] A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets
    Marchetti, P.
    Lupi, R.
    Bugliani, M.
    Kirkpatrick, C. L.
    Sebastiani, G.
    Grieco, F. A.
    Del Guerra, S.
    D'Aleo, V.
    Piro, S.
    Marselli, L.
    Boggi, U.
    Filipponi, F.
    Tinti, L.
    Salvini, L.
    Wollheim, C. B.
    Purrello, F.
    Dotta, F.
    DIABETOLOGIA, 2012, 55 (12) : 3262 - 3272
  • [40] Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists
    Mabilleau, Guillaume
    Pereira, Marie
    Chenu, Chantal
    JOURNAL OF ENDOCRINOLOGY, 2018, 236 (01) : R29 - R42